Fortunately, several molecules have been found to be closely related to thymoma, and PI3K pathway inhibitors as a novel therapy for relapsed or refractory thymoma have been in phase II clinical trials.11 Our results support that high expression of KITLG is an important biomarker for type A and AB thymoma. The gene discussed is KITLG; the disease is thymoma.